Show simple item record

dc.contributor.authorvan de Donk, NWCJ
dc.contributor.authorPalumbo, A
dc.contributor.authorJohnsen, HE
dc.contributor.authorEngelhardt, M
dc.contributor.authorGay, F
dc.contributor.authorGregersen, H
dc.contributor.authorHajek, R
dc.contributor.authorKleber, M
dc.contributor.authorLudwig, H
dc.contributor.authorMorgan, G
dc.contributor.authorMusto, P
dc.contributor.authorPlesner, T
dc.contributor.authorSezer, O
dc.contributor.authorTerpos, E
dc.contributor.authorWaage, A
dc.contributor.authorZweegman, S
dc.contributor.authorEinsele, H
dc.contributor.authorSonneveld, P
dc.contributor.authorLokhorst, HM
dc.contributor.authorEuropean Myeloma Network
dc.date.accessioned2018-07-16T09:04:24Z
dc.date.issued2014-06
dc.identifier.citationHaematologica, 2014, 99 (6), pp. 984 - 996
dc.identifier.issn0390-6078
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2068
dc.identifier.eissn1592-8721
dc.identifier.doi10.3324/haematol.2013.100552
dc.description.abstractMonoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are precursor conditions of multiple myeloma; light-chain monoclonal gammopathy of undetermined significance of light-chain multiple myeloma; and IgM monoclonal gammopathy of undetermined significance of Waldenström's macroglobulinemia and other lymphoproliferative disorders. Clonal burden, as determined by bone marrow plasma cell percentage or M-protein level, as well as biological characteristics, including heavy chain isotype and light chain production, are helpful in predicting risk of progression of monoclonal gammopathy of undetermined significance to symptomatic disease. Furthermore, alterations in the bone marrow microenvironment of monoclonal gammopathy of undetermined significance patients result in an increased risk of venous and arterial thrombosis, infections, osteoporosis, and bone fractures. In addition, the small clone may occasionally be responsible for severe organ damage through the production of a monoclonal protein that has autoantibody activity or deposits in tissues. These disorders are rare and often require therapy directed at eradication of the underlying plasma cell or lymphoplasmacytic clone. In this review, we provide an overview of the clinical relevance of monoclonal gammopathy of undetermined significance. We also give general recommendations of how to diagnose and manage patients with monoclonal gammopathy of undetermined significance.
dc.formatPrint-Electronic
dc.format.extent984 - 996
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectEuropean Myeloma Network
dc.subjectHumans
dc.subjectCell Transformation, Neoplastic
dc.subjectPrecancerous Conditions
dc.subjectDisease Progression
dc.subjectDiagnosis, Differential
dc.subjectPrognosis
dc.subjectDisease Management
dc.subjectMonoclonal Gammopathy of Undetermined Significance
dc.subjectWatchful Waiting
dc.titleThe clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
dc.typeJournal Article
rioxxterms.versionofrecord10.3324/haematol.2013.100552
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2014-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfHaematologica
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.publication-statusPublished
pubs.volume99
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMorgan, Gareth Johnen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0